Literature DB >> 9105685

Tyrosinase mRNA is expressed in human substantia nigra.

Y Xu1, A H Stokes, W M Freeman, S C Kumer, B A Vogt, K E Vrana.   

Abstract

Dopamine acts, under appropriate conditions, as a selective neurotoxin. This toxicity is attributed to the autoxidation of the neurotransmitter into a reactive quinone that covalently modifies cellular macromolecules (i.e. proteins and nucleic acids). The oxidation of the catecholamine to a quinone is greatly accelerated by the enzyme tyrosinase. There is controversy, however, as to whether or not tyrosinase is expressed in human brain. In the present study, RT-PCR was utilized to demonstrate the presence of tyrosinase mRNA in post-mortem human brain tissues. Using gene-specific amplification primers, specific tyrosinase amplicons were detected following analysis of RNA from substantia nigra of four individuals. Analysis of cerebellar RNA from the same individuals produced no amplification products. Control reactions performed in the absence of reverse transcriptase failed to generate PCR products for any tissue tested. Three amplicons were subjected to direct DNA sequencing and all proved to be identical with tyrosinase sequences, thus obviating the possibility of amplification of a related gene. It is clear, therefore, that the tyrosinase gene is expressed in the human substantia nigra, lending support to previous studies describing tyrosinase-like activity and immunoreactive protein in the brain. This enzyme could be central to dopamine neurotoxicity as well as contribute to the neurodegeneration associated with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105685     DOI: 10.1016/s0169-328x(96)00308-7

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  28 in total

Review 1.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

2.  Metazoan innovation: from aromatic amino acids to extracellular signaling.

Authors:  Katrina M Kutchko; Jessica Siltberg-Liberles
Journal:  Amino Acids       Date:  2013-05-21       Impact factor: 3.520

Review 3.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

Review 4.  Copper active sites in biology.

Authors:  Edward I Solomon; David E Heppner; Esther M Johnston; Jake W Ginsbach; Jordi Cirera; Munzarin Qayyum; Matthew T Kieber-Emmons; Christian H Kjaergaard; Ryan G Hadt; Li Tian
Journal:  Chem Rev       Date:  2014-03-03       Impact factor: 60.622

5.  Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase.

Authors:  M Rios; B Habecker; T Sasaoka; G Eisenhofer; H Tian; S Landis; D Chikaraishi; S Roffler-Tarlov
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

Review 6.  Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.

Authors:  Rainer Knörle
Journal:  Neurotox Res       Date:  2017-09-06       Impact factor: 3.911

7.  Effects of quercetin on mushroom tyrosinase and B16-F10 melanoma cells.

Authors:  Isao Kubo; Teruhiko Nitoda; Ken-ichi Nihei
Journal:  Molecules       Date:  2007-05-15       Impact factor: 4.411

8.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

Review 9.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 10.  Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson's disease.

Authors:  Takafumi Hasegawa
Journal:  Int J Mol Sci       Date:  2010-03-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.